COST-EFFECTIVENESS ANALYSIS OF ADD-ON ALISKIREN TO LOSARTAN TREATMENT FOR PATIENTS WITH TYPE 2 DIABETES, HYPERTENSION AND NEPHROPATHY IN THE CZECH PATIENTS FROM PAYOR PERSPECTIVE

被引：0
|
作者：
Kutscherauer, P. [1 ]
Kodym, R. [1 ]
Bartaskova, D. [2 ]
机构：
[1] Novartis Pharmaceut, Prague, Czech Republic
[2] Charles Univ Prague, Prague, Czech Republic
来源：
VALUE IN HEALTH | 2009年 / 12卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)73833-X
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A154 / A154
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness of aliskiren as add on to losartan and optimal an tihypertensive therapy in patients with type 2 diabetes, hypertension and nephropathy in the UK setting
    Palmer, James L.
    Munk, Veronica C.
    Kotchie, Robert W.
    Vincze, Gabor
    Charney, Alan
    Tucker, Daniel M. D.
    Annemans, Lieven
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2008, 51 (04) : A76 - A76
  • [2] The cost-effectiveness of aliskiren as add on to losartan and optimal antihypertensive therapy in patients with type 2 diabetes, hypertension and nephropathy in the United Kingdom setting
    Palmer, J. L.
    Munk, V. C.
    Kotchie, R.
    Vincze, G.
    Charney, A.
    Tucker, D.
    Annemans, L.
    [J]. VALUE IN HEALTH, 2008, 11 (03) : A196 - A196
  • [3] Cost-effectiveness of aliskiren added to losartan and optimal antihypertensive therapy in patients with hypertension, type 2 diabetes, and nephropathy by age
    Delea, Thomas E.
    Sofrygin, Oleg
    Palmer, James L.
    Annemans, Liev-En
    Lau, Helen
    Munk, Veronica C.
    Sung, Jennifer
    Charney, Alan
    Sullivan, Sean D.
    [J]. DIABETES, 2008, 57 : A137 - A137
  • [4] Cost effectiveness of losartan in the treatment of patients with type 2 diabetes and nephropathy in Greece
    Sarafidis, P. A.
    Stafylas, R. C.
    Lasaridis, A. N.
    Grekas, D. M.
    Dombros, N. V.
    Tsakni, E.
    Aletras, V. H.
    Niakas, D. A.
    Bakris, G. L.
    [J]. JOURNAL OF HYPERTENSION, 2006, 24 : S140 - S140
  • [5] COST-EFFECTIVENESS ANALYSIS OF LINAGLIPTIN VERSUS SULFONYLUREA AS ADD-ON TREATMENT TO METFORMIN FOR THE TREATMENT OF DIABETES MELLITUS TYPE 2 PATIENTS IN INDONESIA
    Endarti, D.
    Kristin, E.
    Pratiwi, W. R.
    Pinzon, R. T.
    Nugrahaningsih, D. A.
    Yasmina, A.
    Febrinasari, R. P.
    [J]. VALUE IN HEALTH, 2018, 21 : S39 - S39
  • [6] Cost-Effectiveness of Aliskiren in Type 2 Diabetes, Hypertension, and Albuminuria
    Delea, Thomas E.
    Sofrygin, Oleg
    Palmer, James L.
    Lau, Helen
    Munk, Veronica C.
    Sung, Jennifer
    Charney, Alan
    Parving, Hans-Henrik
    Sullivan, Sean D.
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2009, 20 (10): : 2205 - 2213
  • [7] COST-EFFECTIVENESS OF DAPAGLIFLOZIN AS ADD-ON TO INSULIN FOR THE TREATMENT OF TYPE 2 DIABETES IN THE NETHERLANDS
    van Haalen, H. G. M.
    Pompen, M.
    Bergenheim, K.
    McEwan, P.
    Townsend, R.
    Roudaut, M.
    [J]. VALUE IN HEALTH, 2013, 16 (07) : A441 - A441
  • [8] COST-EFFECTIVENESS OF DAPAGLIFLOZIN AS ADD-ON TO METFORMIN FOR THE TREATMENT OF TYPE 2 DIABETES IN GREECE
    Tzanetakos, C.
    Tentolouris, N.
    Kourlaba, G.
    Maniadakis, N.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A606 - A607
  • [9] A cost-effectiveness analysis of linagliptin add-on to insulin treatment for patients with type 2 diabetes mellitus and chronic kidney disease in Iran
    Fariman, Soroush Ahmadi
    Nosrati, Marzieh
    Rahmani, Parham
    Nikfar, Shekoufeh
    [J]. JOURNAL OF DIABETES AND METABOLIC DISORDERS, 2023, 22 (02) : 1263 - 1271
  • [10] A cost-effectiveness analysis of linagliptin add-on to insulin treatment for patients with type 2 diabetes mellitus and chronic kidney disease in Iran
    Soroush Ahmadi Fariman
    Marzieh Nosrati
    Parham Rahmani
    Shekoufeh Nikfar
    [J]. Journal of Diabetes & Metabolic Disorders, 2023, 22 : 1263 - 1271
12345